46th week of 2015 patent applcation highlights part 9 |
Patent application number | Title | Published |
20150320716 | CHLOROPROCAINE-BASED PHARMACEUTICAL COMPOSITION FOR REPEATED INTRATHECAL ADMINISTRATION - This invention relates to an injectable pharmaceutical composition based on chloroprocaine or salts and/or derivatives thereof for use in central loco-regional anesthesia by intrathecal administration in repeated doses. Unexpectedly, the intrathecal administration in repeated doses of chloroprocaine does not increase the neurotoxicity of this drug in statistically significant manner. | 2015-11-12 |
20150320717 | Methods Of Using Low-Dose Doxepin For The Improvement Of Sleep - Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg). | 2015-11-12 |
20150320718 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS - The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed. | 2015-11-12 |
20150320719 | DELPHINIDIN FOR COMBATING MELANOMA CELLS - The invention relates to a composition comprising: a complex of delphinidin and a sulfoalkyl ether-β-cyclodextrin and/or delphinidin and the salts thereof as a first component; and a tumour-necrosis factor related apoptosis-inducing ligand (TRAIL) as a second component, for use in the treatment of malignant melanoma. | 2015-11-12 |
20150320720 | METHODS AND COMPOSITIONS FOR TREATING CANCER - This disclosure provides compositions and method useful for treating cell proliferative disorders including cancer. The disclosure provides cannabidiol derivatives and compositions thereof either alone or in combination with THC or a derivative thereof. | 2015-11-12 |
20150320721 | COMBINATIONS OF SGLT 2 INHIBITORS AND ANTIHYPERTENSIVE DRUGS - Medicaments that depend on a combination of SGLT 2 inhibitors and antihypertensive drugs and which are useful in the treatment of diseases involving at least hypertension or diabetes mellitus as a risk factor of cardiovascular events, as well as methods of treating the diseases are provided. Since the present invention exhibits a superior hypotensive action that cannot be attained by any single antihypertensive drugs, the conventional problems associated with the use of two or more antihypertensive drugs in order to lower the blood pressure to the desired level can be solved. In addition, the present invention shows a marked therapeutic efficacy in diabetes mellitus, a disease associated with diabetes mellitus, or complications of diabetes mellitus, in particular, diabetic nephropathy. As a further advantage, the present invention is also useful for the treatment of diseases involving lowered renal function. | 2015-11-12 |
20150320722 | FORMULATION FOR SOFT ANTICHOLINERGIC ANALOGS - Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis. | 2015-11-12 |
20150320723 | Use of Small Molecule Unfolder Protein Response Modulators to Treat Tumors With Active Sonic Hedgehog (SSH) Signaling Due To Smoothened (SMO) Mutation - The present invention relates to methods for treating tumors having SMO mutations as well as diagnosing tumors with SMO mutations. The invention relates to methods for the treatment of cancer with ER stress-inducing compounds or UPR inducing compounds. The ER stress-inducing compounds or UPR inducing compounds might fill a clinical need for additional methods of targeting the Hh pathway, either in frontline combination therapy or in salvage therapy for relapsed patients who develop resistance to the available SMO inhibitor and offer a significant advantage over SMO-specific small molecules. Because ER stress modulators and UPR inducing compounds exploit a cellular process that is distinct from the Hh signaling pathway, their efficacy should be unaltered by acquired SMO mutation. | 2015-11-12 |
20150320724 | METHODS OF TREATING DIABETES BY ADMINISTERING A GLUCAGON RECEPTOR ANTAGONIST IN COMBINATION WITH A CHOLESTEROL ABSORPTION INHIBITOR - Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed. | 2015-11-12 |
20150320725 | Use of Organic Compound for the Treatment of Noonan Syndrome - The use of a MEK inhibitor compound of Formula (I), as defined herein, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of Noonan Syndrome, a method of treating a warm-blooded animal, especially a human, having Noonan Syndrome, comprising administering to said animal a therapeutically effective amount of a MEK inhibitor compound of Formula (I), as defined herein, or a pharmaceutically acceptable salt thereof, and to a pharmaceutical composition and a commercial package comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a package insert or other labeling including directions for treating Noonan Syndrome. | 2015-11-12 |
20150320726 | METHOD FOR TREATING OBESITY - The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism. | 2015-11-12 |
20150320727 | HETEROCYCLIC COMPOUNDS AND USES THEREOF - Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein. | 2015-11-12 |
20150320728 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE ANTIBODY RESPONSES - Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class II-restricted epitopes and immunosuppressants that provide tolerogenic immune responses, such as a reduction in CD4+T cell help specific to an antigen. | 2015-11-12 |
20150320729 | PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC PYRIDINOL DERIVATIVES FOR PREVENTING OR TREATING DISEASES CAUSED BY ANGIOGENESIS - Disclosed is a pharmaceutical composition including a bicyclic pyridinol derivative as an active ingredient for preventing or treating diseases caused by angiogenesis. The bicyclic pyridinol derivative expressed by Chemical Formula 1 can be effectively used as a drug for preventing and treating diseases caused by angiogenesis since it inhibits neovascularization in a chorioallantoic membrane model. | 2015-11-12 |
20150320730 | GPBP-1 inhibition and its therapeutic use - The present invention provides compositions including anti-tumor agents and inhibitors of Goodpasture antigen binding protein, p21, and ABCC7, and their use in treating cancer. | 2015-11-12 |
20150320731 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR - Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 2015-11-12 |
20150320732 | Retinoid Topical Compositions and Methods for Treating Skin Conditions - A topical pharmaceutical composition comprising tazarotene and one or more of an anti-inflammatory or anti-bacterial agent. Also provided is a method for treating skin conditions, such as acne utilizing the above topical pharmaceutical composition. | 2015-11-12 |
20150320733 | INDAZOLE COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS - This invention relates to indazole compounds of the structural formula: (structure represented) or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment or amelioration of conditions that could be treated by inhibiting aldosterone synthase. | 2015-11-12 |
20150320734 | TREATMENT FOR CEREBRAL PALSY GAIT IMPAIRMENT - A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a child to treat a gait impairment secondary to cerebral palsy, or a gait impairment resultant side effect from anti-cancer and anti-seizure drugs. The administered methylphenidate simultaneously treats speech and gait or limb impairments secondary to a disease or disorder. | 2015-11-12 |
20150320735 | METHOD FOR TREATING/PREVENTING DISEASE USING COGNITIVE ABILITY OF CEREBRUM AND PHARMACEUTICAL - An object of the present invention is to develop a method of enhancing the cognitive ability of a brain to fundamentally cure a disease. It has been found out that, by using a medicament for treating or preventing a disease including a combination of a major tranquilizer, and vitamin C or a salt thereof and, if necessary, drip infusion, an antidepressant and an iron agent, the cognitive ability of a brain is enhanced, thus, an arbitrary disease including various cancers can be treated. The present invention also provides a method for treating or preventing a disease including a step of administering a major tranquilizer, and vitamin C or a salt thereof to a subject suffering from the disease. | 2015-11-12 |
20150320736 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES - The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed. | 2015-11-12 |
20150320737 | LFA-1 INHIBITOR FORMULATIONS - The present invention provides formulations, methods and kits for the treatment of dry eye diseases. In particular, stabilized pharmaceutical compositions comprising the compound of Formula 1 are described herein for a variety of uses including the treatment of dry eye syndrome. In one aspect, methods and ingredients for improving the stability of compositions of the compound of Formula 1 are described. | 2015-11-12 |
20150320738 | BERBERINE-CONTAINING PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER STEM CELL GROWTH OR CARCINOMA METASTASIS AND APPLICATION THEREOF - A pharmaceutical composition for inhibiting cancer stem cells growth or carcinoma metastasis and an application thereof are disclosed. The pharmaceutical composition includes: a berberine compound; and a pharmaceutically acceptable carrier. The application is the use of the berberine compound in the manufacture of a medicament for the inhibition of cancer stem cell growth or carcinoma metastasis. | 2015-11-12 |
20150320740 | ENHANCED DELIVERY OF DRUG COMPOSITIONS TO TREAT LIFE THREATENING INFECTIONS - Inhalable compositions are described. The inhalable compositions comprise one or more respirable aggregates, the respirable aggregates comprising one or more poorly water soluble active agents, wherein at least one of the active agents reaches a maximum lung concentration (C | 2015-11-12 |
20150320741 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST - The present invention relates to combinations of a DGAT inhibitor and a peroxisome proliferator-activator receptor (PPAR) agonist or a prodrug thereof. The invention further relates to methods for preparing such combinations, pharmaceutical compositions comprising said combinations as well as the use as a medicament of said combinations. | 2015-11-12 |
20150320742 | COMBINATIONS COMPRISING 3-PHENYLSULFONYL-8-PIPERAZINYL-1YL-QUINOLINE - The combination of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or a pharmaceutically acceptable salt thereof with a second therapeutic agent, wherein the second therapeutic agent is selected from:
| 2015-11-12 |
20150320743 | INJECTABLE COMBINATION OF ADRENERGIC RECEPTOR AGONISTS WITH FILLERS, FOR DECREASING SKIN REACTIONS DUE TO INJECTION - The present invention concerns an injectable composition comprising a filler or a botulinum toxin and an adrenergic receptor agonist, and its use for diminishing, decreasing or avoiding skin reactions due to injection, specially redness, ecchymosis, bruising, bleeding, erythema, oedema, necrosis, ulceration, swelling and/or inflammation. | 2015-11-12 |
20150320744 | Preparations and Methods for Ameliorating or Reducing Presbyopia - This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. The invention further provides for a method for treating, ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a pharmaceutically effective amount of the ophthalmic preparation. | 2015-11-12 |
20150320745 | Pyrazine Derivatives and Uses Thereof in Renal Monitoring - The present invention relates to pyrazine derivatives such as those represented by Formulas I and II below. | 2015-11-12 |
20150320746 | PHARMACEUTICAL FORMULATION COMPRISING 2,3-DIMETHYL-6-(N,N-DIMETHYLAMINOETHYL)-6H-INDOLO-(2,3-B)QUINOXALINE - A pharmaceutical composition for topical administration including 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline (B-220) or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier. The composition is useful for the treatment of herpes virus infections of the skin or mucous membranes in a mammal subject. | 2015-11-12 |
20150320747 | OSMOLYTE-CONTAINING PREPARATION FOR THE TREATMENT OF DRY MUCOUS MEMBRANES - The present invention relates to osmolyte-containing preparations for the local treatment of dry mucous membranes. It describes the use of osmolytes for the production of a medicament, medical product or cosmetic product for the prevention, therapy and/or care of dry mucous membranes. The present invention relates to topical compositions based on osmolytes to which sodium chloride and/or moisturizers can optionally be added. The group of osmolytes proposed by the invention embraces various low-molecular substances, in particular ectoine, homoectoine, hydroxyectoine, di-myo-inositol phosphate (DIP), cyclic 2,3-diphosphoglycerate (cDPG), 1,1-di-glycerol phosphate (DGP), β-mannosylglycerate (Firoin), β-mannosylglyceramide (Firoin-A), di-mannosyl di-inositol phosphate (DMIP), glucosylglycerol and/or a derivative, e.g. an acid, salt or ester, of these compounds. | 2015-11-12 |
20150320748 | AGENT FOR INHIBITING EXPRESSION OF LIPID METABOLISM RELATED MRNA - The present invention is intended to provide a pharmaceutical product for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the present invention is also intended to provide a preventive and/or therapeutic agent for various diseases based on inhibition of expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and the present invention relates to an agent for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and relates also to a preventive and/or therapeutic agent for various diseases based on the inhibition of the expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the agent comprising a compound represented by Formula (I), its salt, or a solvate of any of them as an active ingredient: | 2015-11-12 |
20150320749 | IMMEDIATE RELEASE 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imida- zol-1-yl)-3-(trifluoromethyl)phenyl] benzamide FORMULATION - A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1 H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coating said core, wherein disintegration of said solid dosage form is delayed | 2015-11-12 |
20150320750 | Composition for Treating or Preventing Diseases Caused by Vascular Permeability, Containing Imatinib or Pharmaceutically Acceptable Salt Thereof as Active Ingredient - The present invention relates to a pharmaceutical composition for treating or preventing diseases caused by vascular permeability, containing imatinib, which has been conventionally used as an agent for treating chronic myeloid leukemia, or a pharmaceutically acceptable salt thereof as an active ingredient, and a method for treating disease caused by vascular permeability using the composition. The pharmaceutical composition for treating or preventing diseases caused by vascular permeability of the present invention contains imatinib, which has been conventionally used as an agent for treating chronic myeloid leukemia, as an active ingredient, so as to provide a novel use of imatinib and to be able to effectively treat or prevent diseases caused by vascular permeability, and thus may be widely applied to develop a novel agent for treating diseases caused by vascular permeability. | 2015-11-12 |
20150320751 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor - The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof: | 2015-11-12 |
20150320752 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES - The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them. | 2015-11-12 |
20150320753 | PURINE DERIVATIVE COMPOUNDS FOR MEDICAL USE - A method for treatment of disease by reduction in macrophages-mediated bacterial killing, including administration to patients in need a compound of formula (I): | 2015-11-12 |
20150320754 | COMBINATION THERAPIES - Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor, or pharmaceutically acceptable form thereof, in combination with a second agent, or a pharmaceutically acceptable form thereof, wherein the second agent is chosen from one or more of 1) a CDK4/6 inhibitor, 2) an HDAC inhibitor, 3) a MEK inhibitor, 4) a mTOR inhibitor, 5) an AKT inhibitor, 6) a proteasome inhibitor, 7) an immunomodulator, 8) a glucocorticosteroid, 9) a BET inhibitor, 10) an epigenetic inhibitor, 11) a PI3K alpha inhibitor, 12) a topoisomerase inhibitor, or 13) an ERK inhibitor. Also provided herein are methods of treatment comprising administration of the compositions, and uses of the compositions, e.g., for treatment of cancer. | 2015-11-12 |
20150320755 | COMBINATION THERAPIES - Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor or a pharmaceutically acceptable form thereof, and a Bcl-2 inhibitor or a pharmaceutically acceptable form thereof. Also provided herein are methods for treating cancer comprising administration the compositions, and uses of the compositions, e.g., for the treatment of cancer. | 2015-11-12 |
20150320756 | TREATMENTS OF COCCIDIOSIS WITH INTRAMUSCULAR TRIAZINE COMPOSITIONS - The present invention relates to compositions and methods for treating coccidiosis in non-human mammals. More particularly, the invention relates to intramuscular compositions and methods for treating coccidiosis with a triazine. | 2015-11-12 |
20150320757 | GUANIDINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C - Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 2015-11-12 |
20150320758 | SELECTIVE INHIBITORS OF HISTONE DEACTYLASE - Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity. | 2015-11-12 |
20150320759 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES - The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound. | 2015-11-12 |
20150320760 | VALACICLOVIR AND MELOXICAM COMBINATION THERAPY FOR FUNCTIONAL SOMATIC SYNDROMES - The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound valaciclovir and a therapeutically-effective amount of the COX-2 inhibitor meloxicam. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of valaciclovir and meloxicam. | 2015-11-12 |
20150320761 | NEURONAL PAIN PATHWAY - The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk. | 2015-11-12 |
20150320762 | TREATMENT OF PROLIFERATIVE DISEASES WITH PYRIMIDODIAZEPINONES - A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in treating a proliferative disorder, wherein: X is NR | 2015-11-12 |
20150320763 | TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT - Tricyclic indazole compound and its pharmaceutically acceptable salts of acid addition, use thereof, method and intermediates for preparing them, and a pharmaceutical composition containing them. | 2015-11-12 |
20150320765 | HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS - The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone C | 2015-11-12 |
20150320766 | COPPER INTRAUTERINE DEVICE - The invention relates to a copper contraceptive intrauterine system (IUS) with a flexible frame, which system is further capable of releasing a selective progesterone receptor modulator (SPRM), such as ulipristal acetate, for reducing or preventing bleeding side effects. | 2015-11-12 |
20150320767 | PROGESTERONE TREATMENT FOR IMPROVING SLEEP QUALITY - Described herein are therapeutic methods using progesterone and progesterone analogs to improve sleep quality. The methods may be particularly useful to treat subject with perturbed sleep patterns, such as subjects who suffer from mid-sleep period awakenings. | 2015-11-12 |
20150320768 | 17-Hydroxyprogesterone Ester-Containing Oral Compositions and Related Methods - The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier. | 2015-11-12 |
20150320769 | Sulfated-Oxysterol and Oxysterol Sulfation by Hydroxysterol Sulfotransferase Promote Lipid Homeostasis and Liver Proliferation - Methods and compositions for the prevention and treatment of liver damage or disease in a subject in need thereof are provided. The methods involve providing the sulfated oxysterol 25-hydroxycholesterol-3-sulfate (25HC3S) to the subject e.g. by 1) administering 25HC3S to the subject; or 2) overexpressing, in the subject, the hydroxysterol sulfotransferase enzyme SULT2B1b, which catalyzes the sulfation of 25-hydroxycholesterol (25HC) to form 25HC3S. | 2015-11-12 |
20150320770 | NOVEL COMPOSITIONS AND METHODS FOR TREATING PROSTATE CANCER - Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat androgen receptor mediated diseases or conditions. In some embodiments, the solid matrix comprises a polymer. In some embodiments, the polymer is soluble in an aqueous solution. In particular embodiments, the aqueous solution is water. In other embodiments, the aqueous solution has a pH of 5.0 or greater. | 2015-11-12 |
20150320771 | INDOLEALKYLAMINO-WITHASTEROID CONJUGATES AND METHOD OF USE - A group of indolealkylamino-withasteroid conjugates, isolated and purified from | 2015-11-12 |
20150320772 | USE OF ACETYLSALICYLIC ACID TO PREVENT AND/OR TREAT DIABETIC WOUNDS - The present invention relates to acetylsalicylic acid or a salt thereof, at a concentration comprised between 200 and 4800 μM, for use in the prevention and/or treatment of diabetic wounds. | 2015-11-12 |
20150320773 | TREATMENT OF INFLAMMATION - Disclosed herein are methods of treating an inflammatory disease or disorder, as well as pharmaceutical compositions and kits useful for treating an inflammatory disease or disorder. The methods, compositions and kits utilize at least one agent, the at least one agent being capable of exhibiting at least two activities selected from the group consisting of: a) inhibiting CD 14 activity and/or a signaling pathway associated with CD 14 activity; b) inhibiting TLR2 activity and/or a signaling pathway associated with TLR2 activity; and c) inhibiting monocyte chemotaxis. | 2015-11-12 |
20150320774 | FORMULATIONS OF CYCLOPHOSPHAMIDE LIQUID CONCENTRATE - Cyclophosphamide containing compositions preferably in the form of solutions having extended stability are disclosed. The compositions contain cyclophosphamide, ethanol and an ethanol soluble acidifying agent such as citric acid. Ready to dilute or ready to use cyclophosphamide containing composition of the invention maintain high levels cyclophosphamide content after about 18 or 24 months at a temperature of about 5° C. | 2015-11-12 |
20150320775 | FORMULATIONS OF CYCLOPHOSPHAMIDE LIQUID CONCENTRATE - Cyclophosphamide containing compositions preferably in the form of solutions having extended stability are disclosed. The compositions contain cyclophosphamide, ethanol and an ethanol soluble acidifying agent such as citric acid. Ready to dilute or ready to use cyclophosphamide containing composition of the invention maintain high levels cyclophosphamide content after about 18 or 24 months at a temperature of about 5° C. | 2015-11-12 |
20150320776 | METHOD OF INHIBITING HELICOBACTER PYLORI - The present invention relates to a method of inhibiting | 2015-11-12 |
20150320777 | Therapeutic Methods - The present invention features a method for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formulas (II) or (IIB) described herein or a pharmaceutically acceptable salt thereof in combination with one or more alternative Hepatitis C therapeutic agents. | 2015-11-12 |
20150320778 | HUMAN MILK OLIGOSACCHARIDES TO AMELIORATE SYMPTOMS OF STRESS - A nutritional composition comprising at least one human milk oligosaccharide selected from 6′ sialyllactose, lacto-N-neotetraose, lacto-N-tetraose, disialylated lacto-N-tetraose, 3′-fucosyllactose, and 3′-sialyllactose. The nutritional composition is used in a method of reducing stress in an individual in need thereof. | 2015-11-12 |
20150320779 | METHODS AND ASSAYS FOR COMBINATION TREATMENT OF CANCER - The technology described herein is directed to the treatment of cancer, e.g. methods and assays relating to selecting and administering a chemotherapy with or without an EZH2 inhibitor. | 2015-11-12 |
20150320780 | MIXTURE OF FUCOSYLATE LACTOSES - A method to form a mixture containing at least one of 2′-FL (2′-O-fucosyllactose, Fuc(α1-2)Gal(β1-4)Glc) and 3-FL (3-O-fucosyllactose, Gal(β1-4)[Fuc(α1-3)]Glc) characterized in that DFL (difucosyl-lactose, Fuc(α1-2)Gal(β1-4)[Fuc(α1-3)]Glc) is subjected to partial hydrolysis, e.g. enzymatic hydrolysis or acid hydrolysis. | 2015-11-12 |
20150320781 | Compositions and Methods for Topical Diagnostic and Therapeutic Transport - Compositions and methods are provided that are useful for the delivery, including transdermal delivery, of biologically active agents, such as non-protein non-nucleotide therapeutics and protein-based therapeutics excluding insulin, botulinum toxins, antibody fragments, and VEGF. The compositions and methods are particularly useful for topical delivery of antifungal agents and antigenic agents suitable for immunization. Alternatively, the composition can be prepared with components useful for targeting the delivery of the compositions as well as imaging components. | 2015-11-12 |
20150320782 | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor - Methods and kits using a pharmaceutical composition for use in inhibiting ocular angiogenesis or fibrosis are provided herein, such that composition includes a pharmaceutically suitable carrier or diluent and an amount of the inhibitor composition effective to inhibit the angiogenesis or the fibrosis by inhibiting expression and/or activity of a galectin protein or a portion thereof. | 2015-11-12 |
20150320783 | N-METHYLSEROTONIN AND RELATED SUBSTANCES FOR USE IN TREATING / LESSENING THE OCCURRENCE OF HOT FLASHES RELATED TO MENOPAUSE - (commonly known as Japanese pepper) seeds, including its mature seeds, contain the NMS precursor/V-methylserotonin 5-O-B-glucoside (“NMS-glucoside”) present in sufficient concentration and are metabolized with sufficient efficiency so as to provide an effective amount of NMS for use in amelioration of menopausal symptoms, including hot flashes/flushes. The Japanese pepper seeds or Japanese pepper seed extracts can also be used to enrich other sources of NMS or NMS precursors in order to provide a nutraceutical or food supplement for controlling hot flashes. | 2015-11-12 |
20150320784 | EFFECTIVE TREATMENT OF TUMORS AND CANCER WITH TRICIRIBINE AND RELATED COMPOUNDS - The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat tumors and cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug. | 2015-11-12 |
20150320785 | METHODS USED TO IDENTIFY AND TREAT GLIOBLASTOMA - The invention encompasses methods and kits used in the identification of invasive glioblastoma based upon the expression of TROY. The methods and kits also allow prediction of disease outcome as well as therapeutic outcome. | 2015-11-12 |
20150320786 | COMPOUNDS SUITED AS NANOCARRIERS FOR ACTIVE AGENTS AND THEIR USE - The invention relates to a compound suited as entity carrier, having the general formula (I) | 2015-11-12 |
20150320787 | COBALAMIN COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING MUCOSITIS - The disclosure relates to a composition comprising at least 0.02% bioactive cobalamin and a thickener, wherein the composition is a liquid, including a gel and a paste. The bioactive cobalamin may be methylcobalamin, hydroxocobalamin and adenosylcobalamin. The thickener makes the viscosity of composition from about 50 to about 10,000 centipoise. The composition may be applied to mucosal surfaces, a tooth or gums to treat inflammatory, ulcerative and painful conditions of mucosal surfaces such as mucositis, stomatitis, vestibulitis, aphthous ulcerations, and Behcet's syndrome. | 2015-11-12 |
20150320788 | Hyaluronate Compositions - The present invention provides compositions suitable for topical administration to a mammalian subject including sodium hyaluronate and a pharmaceutically acceptable excipient. The present invention also provides methods for making and using the same. | 2015-11-12 |
20150320789 | ORAL COMBINATION FOR THE PREVENTION AND TREATMENT OF BLADDER, PELVIC AND UROGENITAL APPARATUS PATHOLOGIES - The invention describes a pharmaceutical association of active ingredients comprising: curcumin, quercetin, chondroitin sulfate and hyaluronic acid, used for the prevention or treatment of bladder, pelvic and urogenital apparatus pathologies. | 2015-11-12 |
20150320790 | Antacid - A low-viscosity, high pH antacid composition comprising: sodium bicarbonate, potassium bicarbonate; calcium carbonate, sweetener, and water. The concentration of sodium bicarbonate in the composition of the invention is preferably in the range of from 1% to 3% by weight. The concentration of potassium bicarbonate in the composition of the invention is preferably in the range of from 0.5% to 1% by weight. The concentration of calcium carbonate in the composition of the invention is preferably in the range of from 0.25% to 1% by weight. The concentration of sweetener in the composition of the invention is preferably in the range of from 0.02% to 0.04% by weight. The remainder of the composition is a low viscosity transport agent, such as water. Additionally, stabilizers may be added and flavoring/coloring agents may be added. | 2015-11-12 |
20150320791 | SYSTEMS AND METHODS TO IMPROVE ORGAN OR TISSUE FUNCTION AND ORGAN OR TISSUE TRANSPLANT LONGEVITY - The present invention provides for systems and methods for inhaled CO therapy to prevent, attenuate, or delay processes that accelerate the loss of organ or tissue function, thereby increasing the lifespan of transplanted organs or tissues, or slowing the decline of native organs or tissues, or delaying the need for replacement of diseased native organs with organ transplants. Such biological processes that are prevented, attenuated, or delayed include chronic persistent inflammation, fibrosis, scarring, as well as immunologic or autoimmune attack. | 2015-11-12 |
20150320792 | REMEDY FOR GASTRITIS AND GASTRIC ULCER - Provided is a gastritis and gastric ulcer-treating agent, which is prepared and developed by processing solar salt and bamboo tree into heat-treated purple salt, in which the heat-treated salt, which is prepared by firstly heat-treating mineral rich solar salt and bamboo tree at a high temperature, that is, 1,100° C. or more; and two or more time repeating the heat-treating of the first heat-treated salt and bamboo tree under the above-described conditions, includes a large amount of hydrogen sulfide-producing material and has a purple color, and when the heat-treated salt is used along with aspirin, the heat-treated salt has an excellent effect on preventing stomach damage, thereby significantly reducing bleeding, ulcer, and the damage of mucous membrane, induced by aspirin. | 2015-11-12 |
20150320793 | Compositions and Solutions for Colon Cleansing - The invention relates to polysiloxanes contained as defoaming agents, amongst other things, in medicinal compositions such colon cleansing solutions and antiflatulants. The aim of the invention is to further improve the defoaming effect of polysiloxanes and also the compatibility of the agents. According to the invention, the use of calcium sulphate increases the defoaming effect of dimeticon or simeticon as polysiloxane defoaming agents. The invention also relates to PEG-containing colon cleaning solutions based thereon. | 2015-11-12 |
20150320794 | Treatment for candidia infections - A method for treating fungal infections using a metal salt of chlorite alone or in combination with a conventional antifungal agent is disclosed. Treatment is either topical or systemic. | 2015-11-12 |
20150320795 | COMPOSITIONS AND METHODS COMPRISING POLYETHYLENE GLYCOL AND MAGNESIUM FOR TREATMENT OF NEURONAL INJURY - The disclosure provides compositions, methods and kits for treatment of neuronal injury. In one embodiment, the composition comprises polyethylene glycol (PEG), and magnesium in one composition. In another embodiment, the composition comprises PEG, and magnesium, where the PEG is in separate composition and the magnesium is in a separate composition. In yet another embodiment, the PEG and/or the magnesium may be administered to treat spinal cord injury. | 2015-11-12 |
20150320796 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM - Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting” chromium complex, wherein the first chromium complex is absorbed more quickly than the slow-acting chromium complex, and methods of using the same. Also provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising a fast-acting chromium complex and a slow-acting chromium complex, to the individual. | 2015-11-12 |
20150320797 | TWO-COMPONENT CLEANING AND DISINFECTING SYSTEM - A disinfectant, sanitizer, germicide, mildicide, virucide, deodorizer, decontaminator and cleaning formulation for cleaning porous and non-porous materials in hospitals, institutions, farms, hotels, cruise ships, homes, schools and other environments is provided. The cleaning formulation comprises a first component including an aqueous alkaline solution containing a surfactant, a triamine, and a quaternary halide and a second component containing an aqueous stabilized hydrogen peroxide solution. The formulation is activated by combining and mixing the two components. The activated formulation can be applied to a surface to be cleaned and/or sanitized with standard techniques. The two components can also be provided as a disinfectant/sanitizer kit. | 2015-11-12 |
20150320798 | Use of Post-Transplant Cyclophosphamide Treated Allogeneic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor Immunity - The present invention relates to the field of cancer therapy. More specifically, the present invention provides methods and compositions useful for augmenting anti-tumor immunity. In one embodiment, a method for treating or preventing post-allogeneic transplant relapse in a subject who has received post-transplant cyclophosphamide treatment comprises the steps of (a) obtaining a bone marrow sample from the subject; (b) expanding the marrow infiltrating lymphocytes (MILs) present in the sample; and (c) administering the MILs to the subject. In a specific embodiment, the method significantly reduces the likelihood of developing GVHD. | 2015-11-12 |
20150320799 | CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AS ANTI-CANCER THERAPEUTICS - Cytotoxic lymphocytes expressing chimeric antigen receptors (CAR) that target and bind small conjugate molecules (SCM) are disclosed, as well as methods of using the cells and the SCMs in the treatment of cancer. | 2015-11-12 |
20150320800 | Immune Effector Cells Pre-Infected with Oncolytic Virus - Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect based on the combined biotherapeutics. | 2015-11-12 |
20150320801 | USE OF ASC AND ASC-CM TO TREAT ARDS, SARS, AND MERS - Disclosed herein is that the systemic administration of ASC conditioned media diminished LPS-induced lung injury by inhibiting epithelial permeability, neutrophil inflammatory response, and secretion of pro-inflammatory TNFα. It is also shown that ARDS lung is able to retain IV-delivered ASC for a substantial amount of time, with no evidence of the significant cell distribution to other organs at this time point. These findings provide optimization of cell-based and cell-free therapy for the treatment of ARDS, including occurrences of ARDS caused by upper respiratory tract infections such as SARS and MERS. | 2015-11-12 |
20150320802 | Methods Of Maintaining Fat Volume - In one aspect, the invention is directed to a method of delivering fat to one or more sites in an individual in need thereof comprising introducing an effective amount of one or more epineural sheaths comprising adipose tissue to the one or more sites in the individual. In another aspect, the invention is directed to a method of maintaining or augmenting (increasing) fat volume at one or more sites in an individual in need thereof comprising introducing an effective amount one or more epineural sheaths comprising adipose tissue to the one or more sites in the individual. The one or more epineural sheaths comprising adipose tissue is maintained under conditions in which the fat volume is maintained and/or augmented at the one or more sites in the individual. | 2015-11-12 |
20150320803 | Method for production of anti-tumor TRAIL protein - A method for production of anti-tumor TRAIL includes inserting a TRAIL molecule, encoded by a viral vector irreversibly derived from a cell line, into a carrier cell, thereby obtaining a stably TRAIL-producing carrier cell, and wherein the TRAIL molecule includes a soluble molecule. | 2015-11-12 |
20150320804 | Bandage Containing Foetal Fibroblasts and Keratinocytes - The present invention describes a composition comprising a mixture of human foetal keratinocyte cells and human foetal fibroblast cells, the ratio between said keratinocyte and fibroblast cells ranging from 0.75 to 2.5, preferably being 1:1 or 7:3. This composition is advantageously included in a bandage, said bandage preferably being sterile and packaged in a container impermeable to microorganisms. The present invention finally concerns the use of this composition as a drug, in particular for treating a skin defect (wound, burn or ulcer). | 2015-11-12 |
20150320805 | COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS - It was found that bacteria belonging to the genus | 2015-11-12 |
20150320806 | COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN - The present invention provides compositions and methods for treatment or prevention of pain resulting from infection, infection related pain, and non-infectious pain as well as treatment or prevention of infections or adverse health consequences associated with infections. | 2015-11-12 |
20150320807 | STRAIN OF BIFIDOBACTERIUM ANIMALIS SSP. ANIMALIS - The invention relates to a novel strain of | 2015-11-12 |
20150320808 | BIFIDOBACTERIA FOR TREATING CARDIAC CONDITIONS - This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction and congestive heart failure. | 2015-11-12 |
20150320809 | COMPOSITIONS AND METHODS FOR IMPROVING HUMAN HEALTH AND NUTRITION - The present invention provides compositions and methods of promoting human health and nutrition. | 2015-11-12 |
20150320810 | NON-REPLICATING VIRUS-DERIVED PARTICLES AND USES THEREOF - There is described herein a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells while having tropism against immortalized cells. The non-replicating Rhabdovirus-derived particle may have cytolytic tropism against immortalized cells. There is also described a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells but has innate and/or adaptive immune-stimulating properties. | 2015-11-12 |
20150320811 | ALGAL EXTRACT COMPRISING SULPHATED AND NON-SULPHATED POLYANIONIC POLYSACCHARIDES AND USES THEREOF - The present invention relates to an algal extract comprising sulphated and non-sulphated polyanionic polysaccharides, to a method for preparing an algal extract as well as to its therapeutic and prophylactic applications. | 2015-11-12 |
20150320812 | COMPOSITION AND METHOD TO IMPROVE BLOOD LIPID PROFILES AND REDUCE LOW DENSITY LIPOPROTEIN (LDL) PER-OXIDATION IN HUMANS USING ALGAE BASED OILS AND ASTAXANTHIN - In accordance with a non-limiting example, an algae based oil is used in place of a krill oil to treat low density lipoprotein (LDL) oxidation in humans by administering a therapeutic amount of a dietary supplement composition comprising an algae based oil comprising glycolipids and phospholipids and Eicosapentaenoic (EPA) fatty acids in combination with astaxanthin derived from | 2015-11-12 |
20150320813 | USING POMEGRANATE EXTRACTS FOR INCREASING PROSTATE SPECIFIC ANTIGEN DOUBLING TIME - A method of increasing a prostate specific antigen (PSA) doubling time in treating a patient. A subject with rising serum PSA is selected. A composition is administered to the subject comprising a therapeutically effective amount of a pomegranate extract comprising a higher content of high molecular weight polyphenol compared to pomegranate juice from arils. The therapeutically effective amount increases a prostate specific antigen doubling time. The pomegranate extract is formed from an insoluble byproduct component obtained by placing pomegranate solids in an aqueous solution, heating the aqueous solution to between about 60° F. to about 210° F., adding at least one enzyme to the aqueous solution, and removing residual insoluble solid materials from the aqueous solution. | 2015-11-12 |
20150320814 | NUTRACEUTICAL FORMULATION FOR TREATMENT OF ANXIETY AND DEPRESSION - Disclosed are compositions of matter useful for treating anxiety and depression. In one embodiment a nutraceutical composition is administered to a patient in need of said composition comprising of the following combination of ingredients: niacin, magnesium, ashwagandha, passionflower, skullcap, St. John's Wort, gamma aminobutryic acid, chamomile, and L-theanine | 2015-11-12 |
20150320816 | COMPOSITIONS FOR PROMOTION OF WOUND HEALING AND/OR SCAR REDUCTION - The present invention relates to a wound healing and scar reduction composition that is a unique product with key ingredients carefully selected to optimize scar reduction. The composition when used can help reduce the appearance of old and new scars. It is an ideal choice for use on all types of scar tissue including, new scars, old scars, surgical, keloids, hypertrophic, stretch marks and any skin condition that would benefit from barrier protection. | 2015-11-12 |
20150320817 | Compositions and Methods for Increasing the Suppression of Hunger and Reducing the Digestibility of Non-Fat Energy Satiety - The present invention relates to methods for increasing the suppression of hunger and/or increasing the reduction of prospective consumption and/or increasing the reduction of appetite and/or increasing the feeling of satiety and/or reducing non-fat energy uptake in the gastrointestinal tract of a mammal in order to prevent a positive non-fat energy balance, weight gain, overweight and obesity, and to induce a negative non-fat energy balance and weight loss in subjects who wish to reduce their body weight. In particular, feed, food and/or beverages and dietary supplements of the present invention comprises mucilage such as flax seed 10 mucilage and/or one or more active compounds of mucilage useful for increasing the suppression of hunger and/or increasing the reduction of prospective consumption and/or increasing the reduction of appetite and/or increasing the feeling of satiety and/or reducing the digestibility of non-fat energy in the gastrointestinal tract of a mammal. | 2015-11-12 |
20150320818 | METHOD FOR IMPROVING MEMORY OF A SUBJECT USING A COMPOSITION COMPRISING CISTANCHE AND GINKGO EXTRACTS - A method and composition useful for improving memory of a subject are disclosed. The method comprises the step of administering the composition to the subject. The composition consists essentially of | 2015-11-12 |